Welcome to our dedicated page for ACCUSTEM SCIENCES SEC filings (Ticker: ACUT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial updates, FDA feedback, and licensing agreements make AccuStem Sciences Inc (ACUT) filings dense and time-sensitive. Missing a single Form 8-K could mean overlooking a pivotal stem-cell milestone or partnership announcement.
Stock Titan solves that problem. Our platform delivers AI-powered summaries that translate every paragraph of the company’s disclosures—whether it is the AccuStem Sciences quarterly earnings report 10-Q filing or an unexpected 8-K material event—into plain language. Need to monitor AccuStem Sciences insider trading Form 4 transactions before the market reacts? We send real-time alerts the moment a director buys or sells shares, tagging each move as an AccuStem Sciences Form 4 insider transactions real-time update.
Explore the full spectrum of documents without wading through scientific jargon:
- The annual report: AccuStem Sciences annual report 10-K simplified so you can spot R&D spending trends and pipeline risks.
- The proxy: clear guidance on AccuStem Sciences proxy statement executive compensation and board independence.
- Material events: AccuStem Sciences 8-K material events explained, from trial enrollments to patent grants.
Investors use these insights to compare quarter-over-quarter burn rates, track executive stock transactions Form 4, and understand AccuStem Sciences SEC documents with AI—saving hours otherwise spent parsing technical exhibits. Whether you’re after an AccuStem Sciences earnings report filing analysis or simply want AccuStem Sciences SEC filings explained simply, everything updates the instant EDGAR posts.
AccuStem Sciences Inc. (ACUT) reports a key administrative step toward Medicare reimbursement for its MSC test (MicroRNA Signature Classifier), a blood-based assay that helps assess lung cancer risk in patients eligible for low-dose CT screening or with indeterminate pulmonary nodules. The MSC test analyzes 24 circulating microRNAs in plasma to classify nodules as Low or High Risk for malignancy, which may help clinicians avoid unnecessary invasive procedures for benign nodules and focus follow-up on higher-risk patients. The company has submitted an application for a local coverage determination to Novitas Solutions, a Medicare Administrative Contractor for the JL region, and Novitas has determined that the application is complete and valid and will now enter the review queue.
AccuStem Sciences (ACUT) filed its Q3 2025 10‑Q reporting continued losses and tight liquidity. The company posted a net loss of
Shares outstanding were 16,072,267 as of November 12, 2025, up from 12,100,535 at December 31, 2024, reflecting an issuance of 3,971,732 shares for
FAQ
What is the current stock price of ACCUSTEM SCIENCES (ACUT)?
What is the market cap of ACCUSTEM SCIENCES (ACUT)?
